Veno-venous perfusion-induced systemic hyperthermia: case report with perfusion considerations

Vertrees, R.A.; Zwischenberger, J.B.; Woodson, L.C.; Bedell, E.A.; Deyo, D.J.; Chernin, J.M.
May 2001
Perfusion;May2001, Vol. 16 Issue 3, p243
Academic Journal
Cancer cells are more susceptible to destruction by heat than are their normal counterparts. However, optimization of this hyperthermic susceptibility for selective cancer cell kill has been difficult to define and technically difficult to achieve. A whole-body hyperthermic technique - veno-venous perfusion-induced systemic hyperthermia (VV-PISH) was designed in in vitro and in swine experiments to achieve selective hyperthermic cancer cell destruction. In this case report, VV-PISH is studied for its safety and therapeutic efficiency in a Food and Drug Administration (FDA) approved phase-I study, where hyperthermia is used to treat advanced (Stage III B or IV) lung cancer. VV-PISH, utilizing the ThermoChem™ HT system in an extracorporeal circuit, was used to induce hyperthermia to 42.5°C sustained for 120 min. Cooling returned the body temperature to 37°C. After completion of the treatment, the patient was transferred to the intensive care unit on a ventilator, norepinephrine and diuretics. The patient remained somnolent for 36 h, developed pulmonary congestion requiring an additional 48 h before extubation, was transferred to the intermediate unit on day 4 and discharged in good condition on day 8. He did experience hyperthermia-related shrinkage of his lung cancer; however, he succumbed 270 days after this treatment from further progression of this disease. Hyperthermia is not a benign therapy; management techniques have been developed that have ameliorated many of the problems associated with extremely high temperatures, but pathophysiology still exists. Using these techniques, VV-PISH can be safety implemented, albeit not without temporary sequelae and further hospitalization.


Related Articles

  • Greater enhancement of chemosensitivity by caffeine in high-p185neu-expressing human non-small... Tsai, Chun-Ming; Perng, Reury-Perng // JNCI: Journal of the National Cancer Institute;7/6/94, Vol. 86 Issue 13, p1018 

    Investigates the hypothesis that caffeine can reverse the block to mitosis in the presence of damaged DNA in human non-small-cell lung cancer. Activation of M-phase-promoting factor; Determination of the levels of p185neu expression.

  • Second-line docetaxel superior to erlotinib for EGFR wild-type NSCLC.  // Hem/Onc Today;9/25/2013, Vol. 14 Issue 18, p48 

    The article discusses a study by researcher M.C. Garassimo and colleagues which showed that second-line docetaxel is superior to erlotinib and chemotherapy remains the standard of care for patients with epidermal growth factor receptor (EGFR) wild-type non-small cell lung cancer (NSCLC).

  • Small RNAs and Non-Small Cell Lung Cancer. Tong, Alex W. // Current Molecular Medicine;May2006, Vol. 6 Issue 3, p339 

    Patients with non-small cell lung cancer (NSCLC) are commonly diagnosed with advanced disease and have limited therapeutic options. Experimental treatment approaches including small molecule targeted therapeutics, gene modified tumor vaccines, and viral-based gene therapy have induced tumor...

  • Emerging Role of Stereotactic Radiotherapy (SRT) in the Treatment of Early Stage Non-Small Cell Lung Cancer. Lawson, Joshua D.; Sandhu, Ajay; Jiang, Steve; Mundt, Arno J. // Current Cancer Therapy Reviews;2009, Vol. 5 Issue 4, p281 

    Patients with early stage non small cell lung cancer (NSCLC) have historically been treated by resection alone, with results that have been superior to the results seen with radiation alone. This reflects the selection bias inherent to any comparison of operative and non-operative patients but...

  • Traitement des cancers bronchiques à petites cellules métastatiques en 2012. Baize, N. // Oncologie;May2012, Vol. 14 Issue 5, p320 

    Systemic chemotherapy plays a major role in the management of patients with Stage IV small-cell lung cancer(SCLC). Despite strong initial chemosensitivity, majority of patients relapse within a few months and few patients survive more than a year. Spontaneous prognosis is wrong for at least six...

  • Radiothérapie en conditions stéréotaxiques des cancers bronchiques de stade I. Martel-Lafay, I. // Oncologie;May2012, Vol. 14 Issue 5, p282 

    Stereotactic body radiotherapy (SBRT) is an innovative irradiation technique which delivers high dose per fraction in a highly accurate way. It allows to treat medically inoperable patients with non-small cell lung cancer, with impressive local control rates and a very little toxicity. The...

  • Clinical outcomes following image-guided stereotactic body radiation for pulmonary oligometastases. Kim, Daniel; Fuster, Mark M.; Nath, Sameer K.; Bharne, Anjali; Read, William; Bazhenova, Lyudmilla; Song, William Y.; Mundt, Arno J.; Sandhu, Ajay P. // Journal of Radiosurgery & SBRT;2012, Vol. 1 Issue 4, p317 

    Background. Lung is a common site of extracranial metastases. Frameless Stereotactic Body Radiation Therapy (SBRT) is a promising new therapy for unresectable neoplastic lung lesions used at our institution. Methods. A retrospective study of 21 patients and 33 lesions treated with SBRT was done....

  • Expression of CD82/KAI1 and HIF-1α in Non-small Cell Lung Cancer and Their Relationship to Vasculogenic Mimicry. WU, Shiwu; CHENG, Zenong; YU, Lan; SONG, Wenqing; TAO, Yisheng // Chinese Journal of Lung Cancer;Dec2011, Vol. 14 Issue 12, p918 

    Background and objective Vasculogenic mimicry (VM), found in many high invasive ability tumors, is associated with tumor invasion and metastasis. Many genes exhibit abnormal levels of expression in these tumors. This study aims to find good markers for predicting the invasion and metastasis of...

  • Early reduction in tumour [F]fluorothymidine (FLT) uptake in patients with non-small cell lung cancer (NSCLC) treated with radiotherapy alone. Trigonis, Ioannis; Koh, Pek; Taylor, Ben; Tamal, Mahbubunnabi; Ryder, David; Earl, Mark; Anton-Rodriguez, Jose; Haslett, Kate; Young, Helen; Faivre-Finn, Corinne; Blackhall, Fiona; Jackson, Alan; Asselin, Marie-Claude // European Journal of Nuclear Medicine & Molecular Imaging;Apr2014, Vol. 41 Issue 4, p682 

    Purpose: Changes in tumour 3′-deoxy-3′-[F]fluorothymidine (FLT) uptake during concurrent chemo-radiotherapy in patients with non-small cell lung cancer (NSCLC) have been reported, at variable time points, in two pilot positron emission tomography (PET) studies. The aim of this study...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics